M6 | M12 | M18 | M24 | |||||
---|---|---|---|---|---|---|---|---|
Mean ± SD or % | N | Mean ± SD or % | N | Mean ± SD or % | N | Mean ± SD or % | N | |
With any data | 51.8 | 171 | 38.6 | 146 | 42.7 | 141 | 51.8 | 249 |
With data to assess abstinence | 27.6 | 91 | 33.9 | 112 | 33.9 | 112 | 75.5 | 171 |
Abstinent | 57.1 | 52 | 40.2 | 45 | 46.4 | 52 | 41.4 | 103 |
Reasons for the absence of follow-up | ||||||||
No data—lost | 47.8 | 76 | 62.4 | 118 | 38.8 | 128 | 13.3 | 13 |
Impossible to come | 24.8 | 82 | 34.4 | 65 | 15.2 | 50 | 19.4 | 64 |
Death | 0.03 | 1 | 3.2 | 6 | 7.3 | 14 | 21.4 | 21 |
With a psychiatric comorbidity | 56.7 | 97 | 63.7 | 93 | 42.5 | 77 | 48.2 | 120 |
Type of psychiatric comorbidity | 37.7 | |||||||
None | 29.9 | 29 | 42.0 | 39 | 5.19 | 29 | 46.7 | 50 |
Dementia | 0 | 0 | 0 | 0 | 15.5 | 4 | 0 | 0 |
Psychosis | 9.3 | 9 | 18.2 | 17 | 20.7 | 12 | 14.9 | 16 |
Mood disorder | 37.1 | 36 | 20.4 | 19 | 3.9 | 16 | 13.1 | 14 |
Anxiety disorder | 9.3 | 9 | 3.2 | 3 | 24.7 | 3 | 1.9 | 2 |
Personality disorder | 21 | 18 | 20.4 | 19 | 19 | 15.9 | 17 | |
With somatic comorbidity | 11.3 | 11 | 6.5 | 6 | 5.2 | 4 | 5.6 | 6 |
Global Assessment of Functioning | 59.9 ± 19.7 | 70 | 56.7 ± 20.1 | 66 | 59.7 ± 20.6 | 63 | 58.2 ± 19.3 | 88 |
AUDIT score | – | 14.5 ± 12.2 | 130 | – | 14.0 ± 12.1 | 162 | ||
Risk use (score ≤7) | – | 36.2 | 45 | – | 40.1 | 65 | ||
Harmful use (7 < score <13) | – | 13.1 | 17 | – | 6.2 | 10 | ||
Dependence (score ≥13) | – | 50.8 | 66 | – | 50.6 | 82 | ||
BDI | 8.3 ± 7.3 | 163 | 7.8 ± 7.5 | 133 | 7.2 ± 7.1 | 130 | 7.7 ± 7.3 | 168 |
Absent | 29.5 | 48 | 39.1 | 52 | 36.9 | 48 | 40.2 | 68 |
Slight | 25.8 | 42 | 15.8 | 21 | 24.6 | 32 | 20.1 | 34 |
Moderate | 28.8 | 47 | 30.1 | 40 | 25.4 | 33 | 21.3 | 36 |
Severe | 15.9 | 26 | 15.0 | 20 | 13.1 | 17 | 18.3 | 31 |
MCV (UI/L) | 94.9 ± 6.0 | 175 | 95.4 ± 5.9 | 140 | 94.4 ± 5.9 | 141 | 94.3 ± 6.2 | 169 |
% >normal values (n) | 34.9 | 61 | 40 | 56 | 30.5 | 43 | 34.3 | 58 |
TGO (UI/L) | – | – | – | 39.0 ± 55.3 | ||||
% >normal values (n) | 24.6 | 41 | ||||||
TGP (UI/L) | – | – | – | 38.8 ± 61.9 | ||||
% >normal values (n) | 29.9 | 50 | ||||||
GGT (UI/L) | 94.9 ± 6.0 | 175 | 108.0 ± 269.3 | 143 | 112.9 ± 290.8 | 140 | 156.0 ± 379.9 | 168 |
% >normal values (n) | 43.4 | 76 | 40.6 | 58 | 41.4 | 58 | 18.8 | 82 |
Current psychotropic treatment | ||||||||
Neuroleptics | 15.3 | 27 | 13.3 | 20 | 18.0 | 27 | 15.0 | 36 |
Atypical antipsychotics | 25.0 | 44 | 24.6 | 37 | 24.0 | 36 | 23.0 | 55 |
Thymoregulators | 13.6 | 24 | 12.0 | 18 | 12.0 | 18 | 11.3 | 27 |
Antidepressants | 63.0) | 111 | 65.3 | 98 | 62.6 | 94 | 51.8 | 124 |
Anxiolytics | 67.0 | 118 | 65.3 | 98 | 61.3 | 92 | 57.3 | 137 |
Benzodiazepines | 56.2 | 99 | 56.0 | 84 | 11.5 | 38 | 48.9 | 116 |
Related to benzodiazepines | 22.1 | 39 | 17.3 | 26 | 25.1 | 83 | 18.1 | 43 |